Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -85.85% is 13% below its 5-year average of -76.09%, around the middle of its 5-year range (-145.33%–-34.70%).
16.47% above its 12-month average of -102.78%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -21.99%.
RETURN ON ASSETS (ROA)
-85.85%
RETURN ON ASSETS (ROA) AVG TTM
-102.78%
RETURN ON ASSETS (ROA) AVG 3Y
-95.22%
RETURN ON ASSETS (ROA) AVG 5Y
-76.09%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+16.47%
CURRENT VS 3Y AVG
+9.85%
CURRENT VS 5Y AVG
-12.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.10%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
-195.02%
vs the sector median at left
IN8bio, Inc.
Market Cap
$13.62M
Return on Assets (ROA)
-85.85%
TTM Avg
-102.78%
3Y Avg
-95.22%
5Y Avg
-76.09%
Market Cap
$13.72M
Return on Assets (ROA)
-123.23%
TTM Avg
-153.35%
3Y Avg
-205.77%
5Y Avg
-166.29%
Market Cap
$13.25M
Return on Assets (ROA)
-27.12%
TTM Avg
-32.94%
3Y Avg
-35.27%
5Y Avg
-29.16%
Market Cap
$14.01M
Return on Assets (ROA)
-32.53%
TTM Avg
-31.07%
3Y Avg
-30.77%
5Y Avg
-29.89%
Market Cap
$13.10M
Return on Assets (ROA)
-47.98%
TTM Avg
-31.15%
3Y Avg
-42.27%
5Y Avg
-34.21%
Market Cap
$12.86M
Return on Assets (ROA)
-60.93%
TTM Avg
-160.25%
3Y Avg
-205.49%
5Y Avg
-152.09%
Market Cap
$14.39M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.56M
Return on Assets (ROA)
-201.89%
TTM Avg
-113.65%
3Y Avg
-83.24%
5Y Avg
-72.72%
Market Cap
$12.44M
Return on Assets (ROA)
-49.12%
TTM Avg
-29.80%
3Y Avg
-67.98%
5Y Avg
-117.36%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IN8bio, Inc. (INAB) | $13.62M | -85.85% | -102.78% | -95.22% | -76.09% |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | -123.23% | -153.35% | -205.77% | -166.29% |
| Optimi Health Corp. (OPTH)vs › | $13.25M | -27.12% | -32.94% | -35.27% | -29.16% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.01M | -32.53% | -31.07% | -30.77% | -29.89% |
| Cytosorbents Corporation (CTSO)vs › | $13.10M | -47.98% | -31.15% | -42.27% | -34.21% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.86M | -60.93% | -160.25% | -205.49% | -152.09% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.39M | N/A | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.56M | -201.89% | -113.65% | -83.24% | -72.72% |
| Dare Bioscience, Inc. (DARE)vs › | $12.44M | -49.12% | -29.80% | -67.98% | -117.36% |
| IRIDEX Corporation (IRIX)vs › | $12.17M | -13.01% | -15.22% | -24.53% | -20.43% |
ROA
-85.8%
ROE
-101.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -60.22% |
| 2024-12-31 | -145.33% |
| 2023-12-31 | -89.02% |
| 2022-12-31 | -86.33% |
| 2021-12-31 | -34.70% |
| 2020-12-31 | -40.92% |
| 2019-12-31 | -454.34% |
| 2018-12-31 | -35.30% |
